Viral vector platforms within the gene therapy landscape
10.1038/s41392-021-00487-6 · 2021
Lethal immunotoxicity in high-dose systemic AAV therapy
10.1016/j.ymthe.2023.10.015 · 2023
Immune Responses to Viral Gene Therapy Vectors
10.1016/j.ymthe.2020.01.001 · 2020
Interaction of adenovirus with antibodies, complement, and coagulation factors
10.1002/1873-3468.13649 · 2019
Complement System Response to Adeno-Associated Virus Vector Gene Therapy
10.1089/hum.2023.194 · 2024
Evading and overcoming AAV neutralization in gene therapy
10.1016/j.tibtech.2022.11.006 · 2023
Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches
10.1089/hum.2022.138 · 2022
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
10.1056/nejmoa1708538 · 2017
Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations
10.1016/j.omtm.2022.02.011 · 2022
Infection Risk and Safety of Corticosteroid Use
10.1016/j.rdc.2015.08.004 · 2016
Adenovirus Entry: From Infection to Immunity
10.1146/annurev-virology-092818-015550 · 2019
Adenovirus detection by the cGAS/STING/TBK1 DNA sensing cascade
10.1128/jvi.02702-13 · 2014
Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors
10.1038/sj.mt.6300031 · 2007
Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system
10.1016/j.ymthe.2006.03.024 · 2006
Coagulation factor X activates innate immunity to human species C adenovirus
10.1126/science.1226625 · 2012
Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial
10.1016/j.ymthe.2020.01.006 · 2020
Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic
10.1128/jvi.01133-22 · 2022
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
10.1038/sj.gt.3301389 · 2001
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses
10.1016/j.ymthe.2004.09.015 · 2005
PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo
10.1089/10430349950018021 · 1999
Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity
10.1016/j.jconrel.2016.06.022 · 2016
Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia
10.1089/hum.2007.0051 · 2007
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery
10.1016/j.jconrel.2016.07.004 · 2016
Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control
10.1038/s41467-017-02707-6 · 2018
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
10.1182/blood.2021013231 · 2021
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome
10.1126/sciadv.abl8213 · 2021
Adenovirus type 34 and HVR1-deleted Adenovirus type 5 do not bind to PF4: clearing the path towards vectors without thrombosis risk
2022
Ultra-low fouling peptide surfaces derived from natural amino acids
10.1016/j.biomaterials.2009.07.001 · 2009
Hydration behaviors of nonfouling zwitterionic materials
10.1039/d3sc01977b · 2023
Long circulating genetically encoded intrinsically disordered zwitterionic polypeptides for drug delivery
10.1016/j.biomaterials.2018.11.012 · 2019
EKylation: Addition of an Alternating-Charge Peptide Stabilizes Proteins
10.1021/acs.biomac.5b01031 · 2015
Zwitterionic Peptide Cloak Mimics Protein Surfaces for Protein Protection
10.1002/anie.202004995 · 2020
Mitigating the Immunogenicity of AAV-Mediated Gene Therapy with an Immunosuppressive Phosphoserine-Containing Zwitterionic Peptide
10.1021/jacs.2c09484 · 2022
Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
10.2147/ov.s155946 · 2018
Hemocompatibility of zwitterionic interfaces and membranes
10.1038/pj.2014.46 · 2014
Zwitterionic Polymers for Biomedical Applications: Antimicrobial and Antifouling Strategies toward Implantable Medical Devices and Drug Delivery
10.1021/acs.langmuir.4c02664 · 2024
Elucidating Molecular Design Principles for Charge-Alternating Peptides
10.1021/acs.biomac.9b01191 · 2020
Characterization of a permissive epitope insertion site in adenovirus hexon
10.1128/jvi.00256-06 · 2006
High resolution solution structure of the 1.3S subunit of transcarboxylase from Propionibacterium shermanii
10.1021/bi9925367 · 2000
Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting
10.1016/j.virol.2006.01.032 · 2006
